Centre Hospitalier Lyon Sud — Clinical Trial Site

159 Registered trials

44 Currently recruiting

Organisation

Centre Hospitalier Lyon Sud

Location

Pierre-Benite, France

Identifier

ORG-100028244

Address

Chemin Du Grand Revoyet, 69310, France

Departments

-
#1100: Clinical Immunology and Allergy Department
#1201:Hématologie
#2051: Service d’Allergologie et Immunologie Clinique
1302: Service d'Oncologie Médicale
206:Immunologie clinique
250001: Oncology
3300: Hématologie
33005: Oncologie Médicale
4003:Dermatologie
Breast Oncology
Centre Hospitalier Lyon Sud Service d’Hématologie Clinique Pavillon 1F
chirugie Digestive et oncologique
Chirurgie digestive et oncologique
Chirurgie viscérale et digestive
Clinical Haematology
Clinical Hematology
Clinical Hematology Department
Clinical Research
Département d’Oncologie Médicale
Departement de Dermatologie
Department of Clinical Hematology
dermatologie
Dermatology
Dermatology and skin cancer unit
Dermatology Unit
Endocrinologie - Diabète - Nutrition
Endocrinology, Diabetes, Nutrition Department
FR10006: Immunologie clinique
FR30007 Urology
Gastro-entérologie
Gastroenterology
Gynécologie-obstétrique
Hématologie
Hématologie clinique
Hématologie option maladies du sang
Hematologie, Pavillon M. Berard 1F
Hematology
Hematology Department
Medecine Interne
Médecine interne et pathologie vasculaire
Médecine Interne et Vasculaire
Medical Oncology
Medical Oncology Department
N/A
NA
Nephrology
Oncologie
Oncologie / Urologie
Oncologie médicale
Oncologie Médicale, Bâtiment 1F
Oncology
Oncology Department
Pneumologie
Pneumology
pulmonology
Radiothérapie
Radiotherapy
Rhône
Rhumatologie
Service d Hematologie
Service d'Allergologie et d'Immunologie Clinique
Service d'Endocrinologie-Diabète-Nutrition
Service d'Hematolgie
Service d'Hematologie
Service d'Hematologie Clinique
Service d'hématologie clinique lymphoïde
Service d'Hépato-Gastroentérologie
Service d'hépatogastroentérologie
Service d'Oncologie
Service d'oncologie médicale
Service d'Oncologie Médicale – 1F
Service d'Oncologie Médicale Bâtiment 1F
Service d’allergologie et d’immunologie clinique
Service d’Endocrinologie diabétologie maladies métaboliques
Service d’Hématologie
Service d’Hématologie Clinique
Service d’Oncologie Médicale – 1F
Service de Dermatologie
Service de pneumologie
Service dermatologie
Service hématologie
Service Hématologie Clinique
Service Imagerie (Bâtiment 3B)
Service of Endocrinology, Diabetes and Nutrition
Service Oncologie medicale
Service Pneumo-Oncologie
site 004_Allergology and Clinical Immunology Department
Unité de dermatologie
Urology
Urology departement
Z97FR10005: Service d'Hématologie Clinique

Clinical trials at this site (159)

Search interface

AUTOP 2 : Screen-and-treat strategy for vaginal flora abnormalities by molecular biology in pregnant women at high risk of preterm birth: A … Pending

2023-509421-41-03 Bacterial vaginosis 5
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma Recruiting

2023-505200-33-00 Multiple myeloma 5 2026-06-15
MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors… Recruiting

2023-507485-10-00 advanced breast cancer 9 2026-04-21
A Phase 1/2a Study of UCART20x22 in B-Cell Non-Hodgkin Lymphoma [NatHaLi-01] Recruiting

2022-501607-27-00 Relapsed or refractory B-cell Non-Hodgkin lymphoma 7 2026-01-06
ENGIC 02 - PRODIGE 86-FOLFIRINOX SBA- Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanc… Recruiting

2023-505486-92-00 Small bowel adenocarcinoma 4 2024-02-09
A Study of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-po… Recruiting

2023-505604-32-00 Non small cell lung cancer (NSCLC) 5 2024-01-24
A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors Recruiting

2022-502654-14-00 Endometrial cancer 4 2023-09-11
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Ca… Recruiting

2022-501703-27-00 Advanced or Metastatic Non-Clear Cell Renal Cell Carcin 5 2023-07-05
A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting

2022-501354-10-01 axial spondyloarthritis 5 2023-06-21
A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn… Recruiting

2022-501709-11-00 Isocitrate deshydrogenase1 mutation-positive (IDH1m) ac 5 2023-06-06
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 Colon carcinoma 5 2026-05-07
metastatic colorectal cancer Recruiting

2023-504831-42-00 patient with colorectal cancer with hepatic metastasis 5 2025-06-27
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-509787-15-00 Patients with localised prostate cancer and high-risk f 5 2025-02-17
Surgical treatment of large incisional hernia with botulinum toxin A injection: a double-blind randomized controlled trial Recruiting

2023-504554-35-00 incisional hernia 5 2025-01-17
A first-in-human study of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors. Recruiting

2023-509230-19-00 Advance solid tumors 7 2024-11-14
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-fibrosis) Recruiting

2023-509912-27-00 Metabolic Dysfunction-Associated Steatotic Liver Diseas 5 2024-11-07
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-507482-26-00 Castrate-resistant prostate cancer with oligometastases 5 2024-10-04
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate… Recruiting

2024-511309-47-00 moderate thrombocytopenia 4 2024-07-17
Phase I/II, open-label, multi-center study to evaluate the safety and efficacy of glyco-humanized polyclonal antibody directed against tumor… Recruiting

2023-509648-88-00 Peripheral T cells lymphoma (PTCL) 9 2024-07-09
PRODIGE 87 FOXTROT II : Personalising and refining neo-adjuvant chemotherapy in locally advanced but resectable colon cancer in the elderly … Recruiting

2023-505214-23-00 colon carcinoma 5 2024-06-07
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Untreated FLIPI 2-5 Follicular Lymphoma 5 2024-06-03
A study of ASP3082 in adults with advanced solid tumors Recruiting

2022-501590-39-00 Solid Tumor 1 2024-05-22
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Mye… Recruiting

2023-507677-18-00 Chronic Myeloid Leukemia 9 2024-05-17